Rense Buijvoets/LinkedIn
May 26, 2026, 14:23
Rense Buijvoets: What If Clots Could Be Treated Exactly Where They Form?
Rense Buijvoets, Co-owner and Managing director at Sensu, shared a post on LinkedIn:
”1 in 4 deaths worldwide are caused by thrombosis.
What if blood clots could be targeted directly at their source?
TGD001, TargED’s fusion protein in development, binds to blood clots so it can act where it is needed most. By activating plasmin locally, it helps break down VWF and fibrin, allowing the clot to dissolve and blood flow to return.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
May 26, 2026, 14:35Novel Insights Into Congenital and Acquired Coagulopathies – ICHCC
-
May 26, 2026, 14:24Fernanda Orsi: The Growing Impact of Hematology Research in Latin America
-
May 26, 2026, 14:14Fredrick Chalinga: The Reality of Massive Transfusion in Emergency Medicine
-
May 26, 2026, 14:09Tareq Abadl: Slide Method vs Tube Method in Blood Grouping
-
May 26, 2026, 14:07Fernanda Flygare: HI-PEITHO Trial Highlights Benefits of EKOS-Assisted Catheter-Directed Thrombolysis in PE
-
May 26, 2026, 14:05Arvind Kumar: The Science Behind Clot Retraction in Hemostasis
-
May 26, 2026, 14:01Maria Fredin Grupper: WHA79 Adopts Landmark WHO Resolution on Stroke
-
May 26, 2026, 13:54Awareness Enables Diagnosis, Diagnosis Enables Care, and Care Changes Lives – EHC
-
May 26, 2026, 13:47Masoabi Sefojane: Reflections on Bleeding Disorder Care in LMICs From the WFH Africa Regional Workshop